1. Trang chủ
  2. » Thể loại khác

Ebook Robbins basic pathology (9th edition): Part 2

360 225 0

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 360
Dung lượng 41,72 MB

Nội dung

(BQ) Part 1 book Robbins basic pathology presentation of content: Oral cavity and gastrointestinal tract, male genital system and lower urinary tract, female genital system and breast, endocrine system, peripheral nerves and muscles, central nervous system,...and other contents.

See Targeted Therapy available online at studentconsult.com Oral Cavity and Gastrointestinal Tract C H A P T E R 14 C H A P T E R CO N T E N T S ORAL CAVITY  551 Oral Inflammatory Lesions  552 Aphthous Ulcers (Canker Sores)  552 Herpes Simplex Virus Infections  552 Oral Candidiasis (Thrush)  552 Proliferative and Neoplastic Lesions of the Oral Cavity  552 Fibrous Proliferative Lesions  552 Leukoplakia and Erythroplakia  553 Squamous Cell Carcinoma  554 Diseases of Salivary Glands  555 Xerostomia  555 Sialadenitis  555 Neoplasms  555 Odontogenic Cysts and Tumors  557 ESOPHAGUS  558 Obstructive and Vascular Diseases  558 Mechanical Obstruction  558 Functional Obstruction  558 Ectopia  558 Esophageal Varices  559 Esophagitis  559 Lacerations  559 Chemical and Infectious Esophagitis  560 Reflux Esophagitis  560 Eosinophilic Esophagitis  561 Barrett Esophagus  561 Esophageal Tumors  562 Adenocarcinoma  562 Squamous Cell Carcinoma  563 STOMACH  564 Inflammatory Disease of the Stomach  564 Acute Gastritis  564 Acute Peptic Ulceration  565 Chronic Gastritis  566 Peptic Ulcer Disease  568 Neoplastic Disease of the Stomach  569 Gastric Polyps  569 Gastric Adenocarcinoma  570 Lymphoma  571 Carcinoid Tumor  571 Gastrointestinal Stromal Tumor  572 SMALL AND LARGE INTESTINES  573 Intestinal Obstruction  573 The gastrointestinal tract is a hollow tube consisting of the esophagus, stomach, small intestine, colon, rectum, and anus Each region has unique, complementary, and highly integrated functions that together serve to regulate the intake, processing, and absorption of ingested nutrients and the disposal of waste products The intestines also are the principal site at which the immune system interfaces with a diverse array of antigens present in food and gut microbes Thus, it is not surprising that the Hirschsprung Disease  573 Abdominal Hernia  574 Vascular Disorders of Bowel  574 Ischemic Bowel Disease  574 Hemorrhoids  576 Diarrheal Disease  576 Malabsorptive Diarrhea  576 Infectious Enterocolitis  580 Inflammatory Intestinal Disease  586 Sigmoid Diverticulitis  586 Inflammatory Bowel Disease  587 Colonic Polyps and Neoplastic Disease  592 Inflammatory Polyps  592 Hamartomatous Polyps  592 Hyperplastic Polyps  593 Adenomas  593 Familial Syndromes  595 Adenocarcinoma  596 APPENDIX  600 Acute Appendicitis  600 Tumors of the Appendix  601 small intestine and colon frequently are involved by infectious and inflammatory processes Finally, the colon is the most common site of gastrointestinal neoplasia in Western populations In this chapter we discuss the diseases that affect each section of the gastrointestinal tract Disorders that typically involve more than one segment, such as Crohn disease, are considered with the most frequently involved region ORAL CAVITY Pathologic conditions of the oral cavity can be broadly divided into diseases affecting the oral mucosa, salivary glands, and jaws Discussed next are the more common conditions affecting these sites Although common, disorders affecting the teeth and supporting structures are not considered here Reference should be made to specialized texts Odontogenic cysts and tumors (benign and malignant), which are derived from the epithelial and/or 552 C H A P T E R 14 Oral Cavity and Gastrointestinal Tract mesenchymal tissues associated with tooth development, also are discussed briefly ORAL INFLAMMATORY LESIONS Aphthous Ulcers (Canker Sores) These common superficial mucosal ulcerations affect up to 40% of the population They are more common in the first two decades of life, extremely painful, and recurrent Although the cause of aphthous ulcers is not known, they tend to be more prevalent within some families and may be associated with celiac disease, inflammatory bowel disease (IBD), and Behỗet disease Lesions can be solitary or multiple; typically, they are shallow, hyperemic ulcerations covered by a thin exudate and rimmed by a narrow zone of erythema (Fig 14–1) In most cases they resolve spontaneously in to 10 days but can recur Herpes Simplex Virus Infections Most orofacial herpetic infections are caused by herpes simplex virus type (HSV-1), with the remainder being caused by HSV-2 (genital herpes) With changing sexual practices, oral HSV-2 is increasingly common Primary infections typically occur in children between and years of age and are often asymptomatic However, in 10% to 20% of cases the primary infection manifests as acute herpetic gingivostomatitis, with abrupt onset of vesicles and ulcerations throughout the oral cavity Most adults harbor latent HSV-1, and the virus can be reactivated, resulting in a so-called “cold sore” or recurrent herpetic stomatitis Factors associated with HSV reactivation include trauma, allergies, exposure to ultraviolet light, upper respiratory tract infections, pregnancy, menstruation, immunosuppression, and exposure to extremes of temperature These recurrent lesions, which occur at the site of primary inoculation or in adjacent mucosa innervated by the same ganglion, typically appear as groups of small (1 to 3 mm) vesicles The lips (herpes labialis), nasal orifices, buccal mucosa, gingiva, and hard palate are the most common locations Although lesions typically resolve within to 10 days, they can persist in immunocompromised patients, who may require systemic antiviral therapy Morphologically, the lesions resemble those seen in esophageal herpes (see Fig 14–8) and genital herpes (Chapter 17) The infected cells become ballooned and have large eosinophilic intranuclear inclusions Adjacent cells commonly fuse to form large multinucleated polykaryons Oral Candidiasis (Thrush) Candidiasis is the most common fungal infection of the oral cavity Candida albicans is a normal component of the oral flora and only produces disease under unusual circumstances Modifying factors include: • Immunosuppression • The strain of C albicans • The composition of the oral microbial flora (microbiota) Broad-spectrum antibiotics that alter the normal micro­ biota can also promote oral candidiasis The three major clinical forms of oral candidiasis are pseudomembranous, erythematous, and hyperplastic The pseudomembranous form is most common and is known as thrush This condition is characterized by a superficial, curdlike, gray to white inflammatory membrane composed of matted organisms enmeshed in a fibrinosuppurative exudate that can be readily scraped off to reveal an underlying erythematous base In mildly immunosuppressed or debilitated individuals, such as diabetics, the infection usually remains superficial, but can spread to deep sites in association with more severe immunosuppression, including that seen in organ or hematopoietic stem cell transplant recipients, as well as patients with neutropenia, chemotherapy-induced immunosuppression, or AIDS S U M M A RY Oral Inflammatory Lesions • Aphthous ulcers are painful superficial ulcers of unknown etiology that may be associated with systemic diseases • Herpes simplex virus causes a self-limited infection that presents with vesicles (cold sores, fever blisters) that rupture and heal, without scarring, and often leave latent virus in nerve ganglia Reactivation can occur • Oral candidiasis may occur when the oral microbiota is altered (e.g., after antibiotic use) Invasive disease may occur in immunosuppressed individuals PROLIFERATIVE AND NEOPLASTIC LESIONS OF THE ORAL CAVITY Fibrous Proliferative Lesions Figure 14–1  Aphthous ulcer Single ulceration with an erythematous halo surrounding a yellowish fibrinopurulent membrane Fibromas (Fig 14–2, A) are submucosal nodular fibrous tissue masses that are formed when chronic irritation results in reactive connective tissue hyperplasia They Proliferative and Neoplastic Lesions of the Oral Cavity A B Figure 14–2  Fibrous proliferations A, Fibroma Smooth pink exophytic nodule on the buccal mucosa B, Pyogenic granuloma Erythematous hemorrhagic exophytic mass arising from the gingival mucosa occur most often on the buccal mucosa along the bite line and are thought to be reactions to chronic irritation Treatment is complete surgical excision and removal of the source of irritation Pyogenic granulomas (Fig 14–2, B) are pedunculated masses usually found on the gingiva of children, young adults, and pregnant women These lesions are richly vascular and typically are ulcerated, which gives them a red to purple color In some cases, growth can be rapid and raise fear of a malignant neoplasm However, histologic examination demonstrates a dense proliferation of immature vessels similar to that seen in granulation tissue Pyogenic granulomas can regress, mature into dense fibrous masses, or develop into a peripheral ossifying fibroma Complete surgical excision is definitive treatment Leukoplakia and Erythroplakia Leukoplakia is defined by the World Health Organization as “a white patch or plaque that cannot be scraped off and cannot be characterized clinically or pathologically as any other disease.” This clinical term is reserved for lesions that arise in the oral cavity in the absence of any known etiologic factor (Fig 14–3, A) Accordingly, white patches caused by obvious irritation or entities such as lichen planus and candidiasis are not considered leukoplakia Approximately 3% of the world’s population has leukoplakic lesions, of which 5% to 25% are premalignant and may progress to squamous cell carcinoma Thus, until proved otherwise by means of histologic evaluation, all leukoplakias must be considered precancerous A related but less common lesion, erythroplakia, is a red, velvety, possibly eroded area that is flat or slightly depressed relative to the surrounding mucosa Erythroplakia is associated with a much greater risk of malignant transformation than leukoplakia While leukoplakia and erythroplakia may be seen in adults at any age, they typically affect persons between the ages of 40 and 70 years, with a 2 : 1 male preponderance Although the etiology is multifactorial, tobacco use (cigarettes, pipes, cigars, and chewing tobacco) is the most common risk factor for leukoplakia and erythroplakia A B Figure 14–3  Leukoplakia A, Clinical appearance of leukoplakia is highly variable In this example, the lesion is smooth with well-demarcated borders and minimal elevation B, Histologic appearance of leukoplakia showing dysplasia, characterized by nuclear and cellular pleomorphism and loss of normal maturation 553 554 C H A P T E R 14 Oral Cavity and Gastrointestinal Tract MORPHOLOGY Leukoplakia includes a spectrum of histologic features ranging from hyperkeratosis overlying a thickened, acanthotic, but orderly mucosal lesions with marked dysplasia that sometimes merges with carcinoma in situ (Fig 14–3, B) The most severe dysplastic changes are associated with erythroplakia, and more than 50% of these cases undergo malignant transformation With increasing dysplasia and anaplasia, a subjacent inflammatory cell infiltrate of lymphocytes and macrophages is often present Squamous Cell Carcinoma Approximately 95% of cancers of the oral cavity are squamous cell carcinomas, with the remainder largely consisting of adenocarcinomas of salivary glands, as discussed later This aggressive epithelial malignancy is the sixth most common neoplasm in the world today Despite numerous advances in treatment, the overall long-term survival rate has been less than 50% for the past 50 years This dismal outlook is due to several factors, most notably the fact that oral cancer often is diagnosed at an advanced stage Multiple primary tumors may be present at initial diagnosis but more often are detected later, at an estimated rate of 3% to 7% per year; patients who survive years after diagnosis of the initial tumor have up to a 35% chance of developing at least one new primary tumor within that interval The development of these secondary tumors can be particularly devastating for persons whose initial lesions were small Thus, despite a 5-year survival rate greater than 50% for patients with small tumors, these patients often die of second primary tumors Therefore, surveillance and early detection of new premalignant lesions are critical for the long-term survival of patients with oral squamous cell carcinoma The elevated risk of additional primary tumors in these patients has led to the concept of “field cancerization.” This hypothesis suggests that multiple primary tumors develop independently as a result of years of chronic mucosal exposure to carcinogens such as alcohol or tobacco (described next) PATHOGENESIS Squamous cancers of the oropharynx arise through two distinct pathogenic pathways One group of tumors in the oral cavity occurs mainly in persons who are chronic alcohol and tobacco (both smoked and chewed) users Deep sequencing of these cancers has revealed frequent mutations that bear a molecular signature consistent with exposure to carcinogens in tobacco These mutations frequently involve TP53 and genes that regulate the differentiation of squamous cells, such as p63 and NOTCH1 The second group of tumors tends to occur in the tonsillar crypts or the base of the tongue and harbor oncogenic variants of human papillomavirus (HPV), particularly HPV-16 These tumors carry far fewer mutations than those associated with tobacco exposure and often overexpress p16, a cyclin-dependent kinase inhibitor It is predicted that the incidence of HPV-associated oropharyngeal squamous cell carcinoma will surpass that of cervical cancer in the next decade, in part because the anatomic sites of origin—tonsillar crypts, base of tongue, and oropharynx— are not readily accessible or amenable to cytologic screening (unlike the cervix) Notably, the prognosis for patients with HPV-positive tumors is better than for those with HPV-negative tumors The HPV vaccine, which is protective against cervical cancer, offers hope to limit the increasing frequency of HPV-associated oropharyngeal squamous cell carcinoma In India and southeast Asia, chewing of betel quid and paan are important predisposing factors Betel quid is a “witch’s brew” containing araca nut, slaked lime, and tobacco, all wrapped in betel nut leaf It is likely that these tumors arise by a pathway similar to that characterized for tobacco use– associated tumors in the West M O R P H O LO G Y Squamous cell carcinoma may arise anywhere in the oral cavity However, the most common locations are the ventral surface of the tongue, floor of the mouth, lower lip, soft palate, and gingiva (Fig 14–4, A) In early stages, these cancers can appear as raised, firm, pearly plaques or as irregular, roughened, or verrucous mucosal thickenings Either pattern may be superimposed on a background of a leukoplakia or erythroplakia As these lesions enlarge, they typically form ulcerated and protruding masses that have irregular and indurated or rolled borders Histopathologic analysis has shown that squamous cell carcinoma develops from dysplastic precursor lesions Histologic patterns range from well-differentiated keratinizing neoplasms (Fig 14–4, B) to anaplastic, sometimes sarcomatoid tumors However, the degree of histologic differentiation, as determined by the relative degree of keratinization, does not necessarily correlate with biologic behavior Typically, oral squamous cell carcinoma infiltrates locally before it metastasizes The cervical lymph nodes are the most common sites of regional metastasis; frequent sites of distant metastases include the mediastinal lymph nodes, lungs, and liver S U M M A RY Lesions of the Oral Cavity • Fibromas and pyogenic granulomas are common reactive lesions of the oral mucosa • Leukoplakias are mucosal plaques that may undergo malignant transformation • The risk of malignant transformation is greater in erythroplakia (relative to leukoplakia) • A majority of oral cavity cancers are squamous cell carcinomas • Oral squamous cell carcinomas are classically linked to tobacco and alcohol use, but the incidence of HPVassociated lesions is rising Diseases of Salivary Glands relaxant, analgesic, and antihistaminic agents The oral cavity may merely reveal dry mucosa and/or atrophy of the papillae of the tongue, with fissuring and ulcerations, or, in Sjögren syndrome, concomitant inflammatory enlargement of the salivary glands Complications of xerostomia include increased rates of dental caries and candidiasis, as well as difficulty in swallowing and speaking Sialadenitis A B Figure 14–4  Oral squamous cell carcinoma A, Clinical appearance demonstrating ulceration and induration of the oral mucosa B, Histologic appearance demonstrating numerous nests and islands of malignant keratinocytes invading the underlying connective tissue stroma DISEASES OF SALIVARY GLANDS There are three major salivary glands—parotid, submandibular, and sublingual—as well as innumerable minor salivary glands distributed throughout the oral mucosa Inflammatory or neoplastic disease may develop within any of these Xerostomia Xerostomia is defined as a dry mouth resulting from a decrease in the production of saliva Its incidence varies among populations, but has been reported in more than 20% of individuals above the age of 70 years It is a major feature of the autoimmune disorder Sjögren syndrome, in which it usually is accompanied by dry eyes (Chapter 4) A lack of salivary secretions is also a major complication of radiation therapy However, xerostomia is most frequently observed as a result of many com­monly prescribed classes of medications including anticholinergic, antidepressant/ antipsychotic, diuretic, antihypertensive, sedative, muscle Sialadenitis, or inflammation of the salivary glands, may be induced by trauma, viral or bacterial infection, or autoimmune disease The most common form of viral sialadenitis is mumps, which may produce enlargement of all salivary glands but predominantly involves the parotids The mumps virus is a paramyxovirus related to the influenza and parainfluenza viruses Mumps produces interstitial inflammation marked by a mononuclear inflammatory infiltrate While mumps in children is most often a selflimited benign condition, in adults it can cause pancreatitis or orchitis; the latter sometimes causes sterility The mucocele is the most common inflammatory lesion of the salivary glands, and results from either blockage or rupture of a salivary gland duct, with consequent leakage of saliva into the surrounding connective tissue stroma Mucocele occurs most often in toddlers, young adults, and the aged, and typically manifests as a fluctuant swelling of the lower lip that may change in size, particularly in association with meals (Fig 14–5, A) Histologic examination demonstrates a cystlike space lined by inflammatory granulation tissue or fibrous connective tissue that is filled with mucin and inflammatory cells, particularly macrophages (Fig 14–5, B) Complete excision of the cyst and the minor salivary gland lobule constitutes definitive treatment Bacterial sialadenitis is a common infection that most often involves the major salivary glands, particularly the submandibular glands The most frequent pathogens are Staphylococcus aureus and Streptococcus viridans Duct obstruction by stones (sialolithiasis) is a common antecedent to infection; it may also be induced by impacted food debris or by edema consequent to injury Dehydration and decreased secretory function also may predispose to bacterial invasion and sometimes are associated with long-term phenothiazine therapy, which suppresses salivary secretion Systemic dehydration, with decreased salivary secretions, may predispose to suppurative bacterial parotitis in elderly patients following major thoracic or abdominal surgery This obstructive process and bacterial invasion lead to a nonspecific inflammation of the affected glands that may be largely interstitial or, when induced by staphylococcal or other pyogens, may be associated with overt suppurative necrosis and abscess formation Autoimmune sialadenitis, also called Sjögren syndrome, is discussed in Chapter Neoplasms Despite their relatively simple morphology, the salivary glands give rise to at least 30 histologically distinct tumors As indicated in Table 14–1, a small number of these neoplasms account for more than 90% of tumors Overall, 555 556 C H A P T E R 14 Oral Cavity and Gastrointestinal Tract salivary gland tumors are relatively uncommon and represent less than 2% of all human tumors Approximately 65% to 80% arise within the parotid, 10% in the submandibular gland, and the remainder in the minor salivary glands, including the sublingual glands Approximately 15% to 30% of tumors in the parotid glands are malignant By contrast, approximately 40% of submandibular, 50% of minor salivary gland, and 70% to 90% of sublingual tumors are cancerous Thus, the likelihood that a salivary gland tumor is malignant is inversely proportional, roughly, to the size of the gland Salivary gland tumors usually occur in adults, with a slight female predominance, but about 5% occur in children younger than 16 years of age Whatever the histologic pattern, parotid gland neoplasms produce swelling in front of and below the ear In general, when they are first diagnosed, both benign and malignant lesions are usually to 6 cm in diameter and are mobile on palpation except in the case of neglected malignant tumors Benign tumors may be present for months to several years before coming to clinical attention, while cancers more often come to attention promptly, probably because of their more rapid growth However, there are no reliable criteria to differentiate A Table 14–1  Histopathologic Classification and Prevalence of the Most Common Benign and Malignant Salivary Gland Tumors Benign Malignant Pleomorphic adenoma (50%) Warthin tumor (5%) Oncocytoma (2%) Cystadenoma (2%) Basal cell adenoma (2%) Mucoepidermoid carcinoma (15%) Acinic cell carcinoma (6%) Adenocarcinoma NOS (6%) Adenoid cystic carcinoma (4%) Malignant mixed tumor (3%) NOS, not otherwise specified Data from Ellis GL, Auclair PL, Gnepp DR: Surgical Pathology of the Salivary Glands, Vol 25: Major Problems in Pathology, Philadelphia, WB Saunders, 1991 benign from malignant lesions on clinical grounds, and histopathologic evaluation is essential Pleomorphic Adenoma Pleomorphic adenomas present as painless, slow-growing, mobile discrete masses They represent about 60% of tumors in the parotid, are less common in the submandibular glands, and are relatively rare in the minor salivary glands Pleomorphic adenomas are benign tumors that consist of a mixture of ductal (epithelial) and myoepithelial cells, so they exhibit both epithelial and mesenchymal differentiation Epithelial elements are dispersed throughout the matrix, which may contain variable mixtures of myxoid, hyaline, chondroid (cartilaginous), and even osseous tissue In some pleomorphic adenomas, the epithelial elements predominate; in others, they are present only in widely dispersed foci This histologic diversity has given rise to the alternative, albeit less preferred name mixed tumor The tumors consistently overexpress the transcription factor PLAG1, often because of chromosomal rearrangements involving the PLAG1 gene, but how PLAG1 contributes to tumor development is unknown Pleomorphic adenomas recur if incompletely excised: Recurrence rates approach 25% after simple enucleation of the tumor, but are only 4% after wider resection In both settings, recurrence stems from a failure to recognize minute extensions of tumor into surrounding soft tissues Carcinoma arising in a pleomorphic adenoma is referred to variously as a carcinoma ex pleomorphic adenoma or malignant mixed tumor The incidence of malignant transformation increases with time from 2% of tumors present for less than years to almost 10% for those present for more than 15 years The cancer usually takes the form of an adeno­ carcinoma or undifferentiated carcinoma Unfortunately, these are among the most aggressive malignant neoplasms of salivary glands, with mortality rates of 30% to 50% at years M O R P H O LO G Y B Figure 14–5  Mucocele A, Fluctuant fluid-filled lesion on the lower lip subsequent to trauma B, Cystlike cavity (right) filled with mucinous material and lined by organizing granulation tissue Pleomorphic adenomas typically manifest as rounded, welldemarcated masses rarely exceeding 6 cm in the greatest dimension Although they are encapsulated, in some locations (particularly the palate), the capsule is not fully developed, and expansile growth produces protrusions into the surrounding tissues The cut surface is gray-white and typically contains myxoid and blue translucent chondroid (cartilage-like) areas The most striking histologic feature is their characteristic heterogeneity Epithelial Odontogenic Cysts and Tumors Clinical course and prognosis depend on histologic grade Low-grade tumors may invade locally and recur in about 15% of cases but metastasize only rarely and afford a 5-year survival rate over 90% By contrast, high-grade neoplasms and, to a lesser extent, intermediate-grade tumors are invasive and difficult to excise As a result, they recur in 25% to 30% of cases, and about 30% metastasize to distant sites The 5-year survival rate is only 50% A B Figure 14–6  Pleomorphic adenoma A, Low-power view showing a well-demarcated tumor with adjacent normal salivary gland parenchyma B, High-power view showing epithelial cells as well as myoepithelial cells within chondroid matrix material elements resembling ductal or myoepithelial cells are arranged in ducts, acini, irregular tubules, strands, or even sheets These typically are dispersed within a mesenchymelike background of loose myxoid tissue containing islands of chondroid and, rarely, foci of bone (Fig 14–6) Sometimes the epithelial cells form well-developed ducts lined by cuboidal to columnar cells with an underlying layer of deeply chromatic, small myoepithelial cells In other instances there may be strands or sheets of myoepithelial cells Islands of well-differentiated squamous epithelium also may be present In most cases, no epithelial dysplasia or mitotic activity is evident No difference in biologic behavior has been observed between the tumors composed largely of epithelial elements and those composed largely of mesenchymal elements Mucoepidermoid Carcinoma Mucoepidermoid carcinomas are composed of variable mixtures of squamous cells, mucus-secreting cells, and intermediate cells These neoplasms represent about 15% of all salivary gland tumors, and while they occur mainly (60% to 70%) in the parotids, they account for a large fraction of salivary gland neoplasms in the other glands, particularly the minor salivary glands Overall, mucoepidermoid carcinoma is the most common form of primary malignant tumor of the salivary glands It is commonly associated with chromosome rearrangements involving MAML2, a gene that encodes a signaling protein in the Notch pathway MORPHOLOGY Mucoepidermoid carcinomas can grow as large as 8 cm in diameter and, although they are apparently circumscribed, they lack well-defined capsules and often are infiltrative The cut surface is pale gray to white and frequently demonstrates small, mucinous cysts On histologic examination, these tumors contain cords, sheets, or cysts lined by squamous, mucous, or intermediate cells The latter is a hybrid cell type with both squamous features and mucus-filled vacuoles, which are most easily detected with mucin stains Cytologically, tumor cells may be benign-appearing or highly anaplastic and unmistakably malignant On this basis, mucoepidermoid carcinomas are subclassified as low-, intermediate-, or high-grade S U M M A RY Diseases of Salivary Glands • Sialadenitis (inflammation of the salivary glands) can be caused by trauma, infection (such as mumps), or an autoimmune reaction • Pleomorphic adenoma is a slow-growing neoplasm composed of a heterogeneous mixture of epithelial and mesenchymal cells • Mucoepidermoid carcinoma is a malignant neoplasm of variable biologic aggressiveness that is composed of a mixture of squamous and mucous cells ODONTOGENIC CYSTS AND TUMORS In contrast with other skeletal sites, epithelium-lined cysts are common in the jaws A majority of these cysts are derived from remnants of odontogenic epithelium In general, these cysts are subclassified as either inflammatory or developmental Only the most common of these lesions are considered here The dentigerous cyst originates around the crown of an unerupted tooth and is thought to be the result of a degeneration of the dental follicle (primordial tissue that makes the enamel surface of teeth) On radiographic evaluation, these unilocular lesions most often are associated with impacted third molar (wisdom) teeth They are lined by a thin, stratified squamous epithelium that typically is associated with a dense chronic inflammatory infiltrate within the underlying connective tissue Complete removal is curative Odontogenic keratocysts can occur at any age but are most frequent in persons between 10 and 40 years of age, have a male predominance, and typically are located within the posterior mandible Differentiation of the odontogenic keratocyst from other odontogenic cysts is important because it is locally aggressive and has a high recurrence rate On radiographic evaluation, odontogenic keratocysts are seen as well-defined unilocular or multilocular radiolucencies On histologic examination, the cyst lining consists of a thin layer of parakeratinized or orthokeratinized stratified squamous epithelium with a prominent basal cell layer and a corrugated luminal epithelial surface Treatment requires aggressive and complete removal; recurrence rates of up to 60% are associated with inadequate resection Multiple odontogenic keratocysts may occur, particularly in patients with the nevoid basal cell carcinoma syndrome (Gorlin syndrome) In contrast with the developmental cysts just described, the periapical cyst has an inflammatory etiology These 557 558 C H A P T E R 14 Oral Cavity and Gastrointestinal Tract extremely common lesions occur at the tooth apex as a result of long-standing pulpitis, which may be caused by advanced caries or trauma Necrosis of the pulpal tissue, which can traverse the length of the root and exit the apex of the tooth into the surrounding alveolar bone, can lead to a periapical abscess Over time, granulation tissue (with or without an epithelial lining) may develop These are often designated periapical granuloma Although the lesion does not show true granulomatous inflammation, old terminology, like bad habits, is difficult to shed Periapical inflammatory lesions persist as a result of bacteria or other offensive agents in the area Successful treatment, therefore, necessitates the complete removal of the offending material followed by restoration or extraction of the tooth Odontogenic tumors are a complex group of lesions with diverse histologic appearances and clinical behaviors Some are true neoplasms, either benign or malignant, while others are thought to be hamartomatous Odontogenic tumors are derived from odontogenic epithelium, ectomesenchyme, or both The two most common and clinically significant tumors are ameloblastoma and odontoma Ameloblastomas arise from odontogenic epithelium and not demonstrate chondroid or osseous differentiation These typically cystic lesions are slow-growing and, despite being locally invasive, have an indolent course Odontoma, the most common type of odontogenic tumor, arises from epithelium but shows extensive deposition of enamel and dentin Odontomas are cured by local excision S U M M A RY Odontogenic Cysts and Tumors • The jaws are a common site of epithelium-lined cysts derived from odontogenic remnants • The odontogenic keratocyst is locally aggressive, with a high recurrence rate • The periapical cyst is a reactive, inflammatory lesion associated with caries or dental trauma • The most common odontogenic tumors are ameloblastoma and odontoma ESOPHAGUS The esophagus develops from the cranial portion of the foregut It is a hollow, highly distensible muscular tube that extends from the epiglottis to the gastroesophageal junction, located just above the diaphragm Acquired diseases of the esophagus run the gamut from lethal cancers to “heartburn,” with clinical manifestations ranging from chronic and incapacitating disease to mere annoyance OBSTRUCTIVE AND VASCULAR DISEASES Mechanical Obstruction Atresia, fistulas, and duplications may occur in any part of the gastrointestinal tract When they involve the esophagus, they are discovered shortly after birth, usually because of regurgitation during feeding, and must be corrected promptly Absence, or agenesis, of the esophagus is extremely rare Atresia, in which a thin, noncanalized cord replaces a segment of esophagus, is more common Atresia occurs most commonly at or near the tracheal bifurcation and usually is associated with a fistula connecting the upper or lower esophageal pouches to a bronchus or the trachea This abnormal connection can result in aspiration, suf­ focation, pneumonia, or severe fluid and electrolyte imbalances Passage of food can be impeded by esophageal stenosis The narrowing generally is caused by fibrous thickening of the submucosa, atrophy of the muscularis propria, and secondary epithelial damage Stenosis most often is due to inflammation and scarring, which may be caused by chronic gastroesophageal reflux, irradiation, or caustic injury Stenosisassociated dysphagia usually is progressive; difficulty eating solids typically occurs long before problems with liquids Functional Obstruction Efficient delivery of food and fluids to the stomach requires a coordinated wave of peristaltic contractions Esophageal dysmotility interferes with this process and can take several forms, all of which are characterized by discoordinated contraction or spasm of the muscularis Because it increases esophageal wall stress, spasm also can cause small diverticula to form Increased lower esophageal sphincter (LES) tone can result from impaired smooth muscle relaxation with consequent functional esophageal obstruction Achalasia is characterized by the triad of incomplete LES relaxation, increased LES tone, and esophageal aperistalsis Primary achalasia is caused by failure of distal esophageal inhibitory neurons and is, by definition, idiopathic Degenerative changes in neural innervation, either intrinsic to the esophagus or within the extraesophageal vagus nerve or the dorsal motor nucleus of the vagus, also may occur Secondary achalasia may arise in Chagas disease, in which Trypanosoma cruzi infection causes destruction of the myenteric plexus, failure of LES relaxation, and esophageal dilatation Duodenal, colonic, and ureteric myenteric plexuses also can be affected in Chagas disease Achalasia-like disease may be caused by diabetic autonomic neuropathy; infiltrative disorders such as malignancy, amyloidosis, or sarcoidosis; and lesions of dorsal motor nuclei, which may be produced by polio or surgical ablation Ectopia Ectopic tissues (developmental rests) are common in the gastrointestinal tract The most frequent site of ectopic gastric mucosa is the upper third of the esophagus, where it is referred to as an inlet patch Although the presence of such tissue generally is asymptomatic, acid released by gastric Esophagitis mucosa within the esophagus can result in dysphagia, esophagitis, Barrett esophagus, or, rarely, adenocarcinoma Gastric heterotopia, small patches of ectopic gastric mucosa in the small bowel or colon, may manifest with occult blood loss secondary to peptic ulceration of adjacent mucosa Esophageal Varices Instead of returning directly to the heart, venous blood from the gastrointestinal tract is delivered to the liver via the portal vein before reaching the inferior vena cava This circulatory pattern is responsible for the first-pass effect, in which drugs and other materials absorbed in the intestines are processed by the liver before entering the systemic circulation Diseases that impede this flow cause portal hypertension, which can lead to the development of esophageal varices, an important cause of esophageal bleeding A B PATHOGE NESIS One of the few sites where the splanchnic and systemic venous circulations can communicate is the esophagus Thus, portal hypertension induces development of collateral channels that allow portal blood to shunt into the caval system However, these collateral veins enlarge the subepithelial and submucosal venous plexi within the distal esophagus These vessels, termed varices, develop in 90% of cirrhotic patients, most commonly in association with alcoholic liver disease Worldwide, hepatic schistosomiasis is the second most common cause of varices A more detailed consideration of portal hypertension is given in Chapter 15 MORPHOLOGY Varices can be detected by angiography (Fig 14–7, A) and appear as tortuous dilated veins lying primarily within the submucosa of the distal esophagus and proximal stomach Varices may not be obvious on gross inspection of surgical or postmortem specimens, because they collapse in the absence of blood flow (Fig 14–7, B) The overlying mucosa can be intact (Fig 14–7, C) but is ulcerated and necrotic if rupture has occurred Clinical Features Varices often are asymptomatic, but their rupture can lead to massive hematemesis and death Variceal rupture therefore constitutes a medical emergency Despite intervention, as many as half of the patients die from the first bleeding episode, either as a direct consequence of hemorrhage or due to hepatic coma triggered by the protein load that results from intraluminal bleeding and hypovolemic shock Among those who survive, additional episodes of hemorrhage, each potentially fatal, occur in more than 50% of cases As a result, greater than half of the deaths associated with advanced cirrhosis result from variceal rupture C Figure 14–7  Esophageal varices A, Angiogram showing several tortuous esophageal varices Although the angiogram is striking, endoscopy is more commonly used to identify varices B, Collapsed varices are present in this postmortem specimen corresponding to the angiogram in A The polypoid areas are sites of variceal hemorrhage that were ligated with bands C, Dilated varices beneath intact squamous mucosa ESOPHAGITIS Lacerations The most common esophageal lacerations are MalloryWeiss tears, which are often associated with severe retching or vomiting, as may occur with acute alcohol intoxication Normally, a reflex relaxation of the gastroesophageal musculature precedes the antiperistaltic contractile wave associated with vomiting This relaxation is thought to fail during prolonged vomiting, with the result that refluxing gastric contents overwhelm the gastric inlet and cause the esophageal wall to stretch and tear Patients often present with hematemesis The roughly linear lacerations of Mallory-Weiss syndrome are longitudinally oriented, range in length from millimeters to several centimeters, and usually cross the gastroesophageal junction These tears are superficial and not generally require surgical intervention; healing tends to be rapid and complete By contrast, Boerhaave syndrome, characterized by transmural esophageal tears and mediastinitis, occurs rarely and is a catastrophic event The factors 559 560 C H A P T E R 14 Oral Cavity and Gastrointestinal Tract giving rise to this syndrome are similar to those for Mallory-Weiss tears, but more severe Chemical and Infectious Esophagitis The stratified squamous mucosa of the esophagus may be damaged by a variety of irritants including alcohol, corrosive acids or alkalis, excessively hot fluids, and heavy smoking Medicinal pills may lodge and dissolve in the esophagus, rather than passing into the stomach intact, resulting in a condition termed pill-induced esophagitis Esophagitis due to chemical injury generally causes only self-limited pain, particularly odynophagia (pain with swallowing) Hemorrhage, stricture, or perforation may occur in severe cases Iatrogenic esophageal injury may be caused by cytotoxic chemotherapy, radiation therapy, or graft-versushost disease The morphologic changes are nonspecific with ulceration and accumulation of neutrophils Irradiation causes blood vessel thickening adding some element of ischemic injury Infectious esophagitis may occur in otherwise healthy persons but is most frequent in those who are debilitated or immunosuppressed In these patients, esophageal infection by herpes simplex viruses, cytomegalovirus (CMV), or fungal organisms is common Among fungi, Candida is the most common pathogen, although mucormycosis and aspergillosis may also occur The esophagus may also be involved in desquamative skin diseases such as bullous pemphigoid and epidermolysis bullosa and, rarely, Crohn disease Infection by fungi or bacteria can be primary or com­ plicate a preexisting ulcer Nonpathogenic oral bacteria frequently are found in ulcer beds, while pathogenic organisms, which account for about 10% of infectious esophagitis cases, may invade the lamina propria and cause necrosis of overlying mucosa Candidiasis, in its most advanced form, is characterized by adherent, graywhite pseudomembranes composed of densely matted fungal hyphae and inflammatory cells covering the esophageal mucosa The endoscopic appearance often provides a clue to the identity of the infectious agent in viral esophagitis Herpesviruses typically cause punched-out ulcers (Fig 14–8, A), and histopathologic analysis demonstrates nuclear viral inclusions within a rim of degenerating epithelial cells at the ulcer edge (Fig 14–8, B) By contrast, CMV causes shallower ulcerations and characteristic nuclear and cytoplasmic inclusions within capillary endothelium and stromal cells (Fig 14–8, C) Immunohistochemical staining for viral antigens can be used as an ancillary diagnostic tool Reflux Esophagitis The stratified squamous epithelium of the esophagus is resistant to abrasion from foods but is sensitive to acid The submucosal glands of the proximal and distal esophagus contribute to mucosal protection by secreting mucin and bicarbonate More important, constant LES tone prevents reflux of acidic gastric contents, which are under positive pressure Reflux of gastric contents into the lower esophagus is the most frequent cause of esophagitis and the most common outpatient gastrointestinal diagnosis in the United B C A Figure 14–8  Viral esophagitis A, Postmortem specimen with multiple herpetic ulcers in the distal esophagus B, Multinucleate squamous cells containing herpesvirus nuclear inclusions C, Cytomegalovirus-infected endothelial cells with nuclear and cytoplasmic inclusions States The associated clinical condition is termed gastroesophageal reflux disease (GERD) PAT H O G E N E S I S Reflux of gastric juices is central to the development of mucosal injury in GERD In severe cases, duodenal bile reflux may exacerbate the damage Conditions that decrease LES tone or increase abdominal pressure contribute to GERD and include alcohol and tobacco use, obesity, central nervous system depressants, pregnancy, hiatal hernia (discussed later), delayed gastric emptying, and increased gastric volume In many cases, no definitive cause is identified M O R P H O LO G Y Simple hyperemia, evident to the endoscopist as redness, may be the only alteration In mild GERD the mucosal histology is often unremarkable With more significant disease, eosinophils are recruited into the squamous mucosa, followed by neutrophils, which usually are associated with more severe injury (Fig 14–9, A) Basal zone hyperplasia ex­­ ceeding 20% of the total epithelial thickness and elongation of lamina propria papillae, such that they extend into the upper third of the epithelium, also may be present Clinical Features GERD is most common in adults older than 40 years of age but also occurs in infants and children The most frequently reported symptoms are heartburn, dysphagia, and, less often, noticeable regurgitation of sour-tasting gastric contents Rarely, chronic GERD is punctuated by attacks of 896 Index Myxomatous mitral valve clinical features of  390–391 degenerative valve disease as  390–391 morphology of  390b, 390f pathogenesis of  390b N Nasopharyngeal carcinoma  513 Natural killer (NK) cell  105, 125–131 as antitumor effector mechanisms  206 Necrosis clinicopathologic correlation examples for  16–18 morphology of  6f, 9b morphology of cell and tissue injury and  patterns of  9–11 morphology of  10b–11b, 10f–11f Necrotizing arteriolitis  333b–334b Necrotizing enterocolitis (NEC) discussion of  252, 252f premature infants and  249 preterm birth complications and  251 Necrotizing glomerulonephritis, focal and segmental  353b–354b Necrotizing granulomatous vasculitis  353b–354b, 353f Necrotizing vasculitis  117b Necrotizing vasculitis, acute  128 Necrotizing vasculitis, noninfectious  135 Neoplasia See also Tumor, benign; Tumor, malignant cancer and etiology of  198–204 genetic lesions in  173–176 molecular basis of cancer and  173 process of carcinogenesis and  177 tumor immunity and  204–207 characteristics of  164–169, 169f clinical aspects of  207–213 effects of tumor on host and  207–208 grading/staging of  207–208 laboratory diagnosis of  210–213 summary for  209b–210b discussion of  161–162 epidemiology of  169–172 nomenclature for  162–163, 164t Neoplasm characteristics of differentiation/anaplasia and  164–166 local invasion and  167–168 metastasis and  168–169 rate of growth and  166–167 summary for  169b of the penis  657–658, 658f summary of  658b of the salivary glands  555–557, 556t mucoepidermoid carcinoma as  557 pleomorphic adenoma as  556 Neoplasm, benign differentiation and anaplasia of  164 local invasion and  167f–168f metastasis and  168–169 nomenclature for  162 rate of growth of  166–167 summary for  169b, 169f Neoplasm, embryonal  844–845 medulloblastoma as  844–845 neuroectodermal tumors and  844–845 Neoplasm, malignant differentiation and anaplasia of  164–165, 165f local invasion and  167–168, 167f–168f metastasis and  168–169 nomenclature for  162–163 rate of growth of  166 summary for  169b, 169f Neovascularization  251 Nephritic syndrome acute postinfectious glomerulonephritis as  529 glomerular disease and  529–531 hereditary nephritis as  531 IgA nephropathy as  530–531 renal syndromes and  517–518 summary for  531b Nephritis, hereditary clinical course of  531 morphology of  531b nephritic syndromes and  531 pathogenesis of  531b summary for  531 Nephrolithiasis  518 Nephron loss  523 Nephrosclerosis  333b–334b Nephrotic syndrome amyloidosis and  158 focal segmental glomerulosclerosis as  525–526 and glomerular disease  523–528, 524t membranoproliferative glomerulonephritis and dense deposit disease as  527–528 membranous nephropathy as  526–527 minimal-change disease as  524–525 renal diseases and  518 summary for  528b–529b Nervous system infections of  824–831 epidural and subdural infections of  824–825 meningitis as  825–826 parenchymal infections and  826–831 prion diseases and  831 summary for  832b patterns of injury in morphology of  811b–812b, 812f Neural tube defect  822–823, 823f Neuroblastic  258–259 Neuroblastoma of the adrenal medulla  761 clinical course and prognosis for  259–260, 260t discussion of  258–260 morphology of  259b, 259f summary for  260b Neuroborreliosis  826 Neurodegenerative disease Alzheimer disease as  836–837 amyotrophic lateral sclerosis as  841 of the central nervous system  836–841, 836t frontotemporal lobar degeneration as  838 Huntington disease as  840 Parkinson disease as  839–840 spinocerebellar ataxias as  840–841 summary of  841b–842b Neurofibroma morphology of  808b of peripheral nerve sheath  807–808 Neurofibroma, diffuse  807, 808b Neurofibroma, localized cutaneous  807 Neurofibromatosis type 1  808 Neurofibromatosis type 1, familial  179–180 Neurofibromatosis type (NF2)  806–807 Neurohypophysis See Posterior pituitary syndrome Index Neuromuscular junction, disorders of introduction to  800–801 Lambert-Eaton syndrome as  801 miscellaneous disorders of  801 myasthenia gravis as  800–801 summary for  801b Neuromyelitis optica (NMO)  834 Neuropeptides  49 Neurosyphilis  826 Neutropenia  425–426 Neutrophil extracellular trap (NET)  39, 40f Nevus flammeus  357 Newborn, hemolytic disease in  254 NextGen sequencing  265–266, 267f NF2  187–188 Niemann-Pick disease types A and B  230–231, 230f Niemann-Pick disease types C (NPC)  231 Night blindness  297 Nitric oxide (NO)  49–50 Nodular fasciitis  793 Nomenclature benign tumors and  162 malignant tumors and  162–163 for neoplasia  162–163 Nonalcoholic fatty liver disease (NAFLD) introduction to  625 pathogenesis of  625b summary for  625b Nonbacterial thrombotic endocarditis (NBTE)  394–395, 395f Non-coding RNA (ncRNA)  217–218, 217f Nongonococcal urethritis (NGU)  676 summary for  676b Non-infected vegetation Libman-Sacks endocarditis as  395 nonbacterial thrombotic endocarditis as  394–395 Noninfectious vasculitis anti-endothelial cell antibodies as  350 anti-neutrophil cytoplasmic antibodies as  349–350 immune complex-associated vasculitis as  348–350 Nonspecific interstitial pneumonia (NSIP)  473 Nontuberculous mycobacterial disease as chronic pneumonia  499 Norovirus  585 Noxious stimuli, cellular responses to  1–3, 2f Nuclear transcription factor  180 Numeric abnormality, cytogenetic disorders and  235 Nutmeg liver  368 Nutritional disease anorexia nervosa/bulimia as  295–296 diet and cancer as  306 diet and systemic diseases as  306 discussion of  293–306 malnutrition as  293–294 neurologic illnesses and  835 obesity as  302–305 protein-energy malnutrition as  294–295 summary for  302b Nutritional imbalance, cell injury and  O Obesity adipose tissue and  304–305 clinical consequences of  305 gut hormones and  305 leptin and  304 nutritional diseases and  302–305 summary for  305b Obligate intracellular bacteria  311 Obstructive lesion, aortic coarctation and  373–374 Obstructive lung disease asthma as  468–470 bronchiectasis as  470–472 chronic bronchitis as  467 discussion of  463–472, 463t, 464f emphysema as  463–466 Obstructive overinflation  466 Occupational asthma  470 Occupational cancer  171t Oligodendroglioma  843 morphology of  843b–844b, 844f Oligohydramnios sequence  246–247, 247f Oncocytoma  547 Oncofetal antigens  206 Oncogene  173, 182 Oncogene, mutated  204–205 Oncogene addiction  180 Oncology  162 Onion-skin lesion  130 Opsonization  114–115, 115f, 117 Oral candidiasis (thrush)  552 Oral cavity disease of salivary glands and  555–557 odontogenic cysts and tumors of  557–558 oral inflammatory lesions of  552 proliferative and neoplastic lesions of  552–554 summary for  554b Oral contraceptive (OC)  283–284 Oral inflammatory lesion aphthous ulcers as  552 herpes simplex virus infections as  552 oral candidiasis as  552 summary for  552b Organic solvent  276 Organochlorine  276 Organ systems, ionizing radiation effects and  292–293, 292f, 292t Osler-Weber-Rendu disease See Hereditary hemorrhagic telangiectasia Osteitis deformans See Paget disease Osteoarthritis clinical course of  783, 783f the joints and  782–790 morphology of  782b–783b, 782f obesity and  305 pathogenesis of  783b summary for  790 Osteoblastoma  776 morphology of  776b Osteochondroma as cartilage-forming tumors  777–778, 777f clinical features of  778 morphology of  778b summary for  781 Osteogenesis imperfecta (OI)  767–768 Osteoid osteoma as bone-forming tumor  776 morphology of  776b, 776f summary for  781 Osteoma  775–776 Osteomalacia acquired bone disease and  771 morphology of  300b–301b vitamin D and  298–300 Osteomyelitis acquired diseases of bone and  773–774 pyogenic osteomyelitis as  773–774 tuberculous osteomyelitis as  774 897 Index 898 Osteopetrosis  767–768 Osteoporosis acquired bone disease and  768–770, 769t, 772 clinical course of  770 exogenous estrogens and  282–283 morphology of  768b–769b, 769f pathogenesis of  766f, 769b–770b, 769f vitamin D and  299–300 Osteosarcoma bone tumors as  776–777 clinical features of  777 morphology of  776b–777b, 776f pathogenesis of  777b summary for  782 Ostium primum ASD  371b Ostium secundum ASD  371b Outdoor air pollution  272–273 morphology of  273b Ovary follicle and luteal cysts and  695 other tumors of  698–700, 699t polycystic ovarian disease and  695–696 tumors of  696–698 Oxidative stress See Free radicals, oxygen-derived Oxygen deprivation  Ozone  272–273, 272t P Paget disease (osteitis deformans) acquired bone disease as  770–771 clinical course of  771 morphology of  770b, 770f pathogenesis of  771b summary for  772 Paget disease, extramammary  683–684, 684f summary of  684 Paget disease of the nipple  710 Panacinar emphysema  464, 464f, 465b Pancarditis  391b Pancreas congenital anomalies of agenesis and  646 annular pancreas as  646 congenital cysts as  646 ectopic pancreas as  646 pancreas divisum as  646 overview of  645 pancreatic neoplasms and  651–654 pancreatitis and  646–651 Pancreas, congenital cysts of  646 Pancreas, ectopic  646 Pancreas, endocrine diabetes mellitus and  739–750 pancreatic neuroendocrine tumors and  751–752 Pancreas divisum  646 Pancreatic abnormality  223–227 Pancreatic carcinoma clinical features of  654 introduction to  652–654 morphology of  653b–654b, 654f pathogenesis of  653b, 653f Pancreatic neoplasm cystic neoplasms as  651–652 intraductal papillary mucinous neoplasms as  652 mucinous cystic neoplasms as  652 serous cystadenomas as  651 pancreatic carcinoma and  652–654 summary for  654b Pancreatic neuroendocrine tumor (PanNET) endocrine pancreas and  751–752 gastrinomas and  752 insulinomas and  751 Pancreatic pseudocyst acute pancreatitis and  649 morphology of  649b, 649f Pancreatitis acute pancreatitis and  646–649 chronic pancreatitis and  649–651 and the pancreas  646–651 summary for  651b Pancreatitis, acute clinical features of  648–649 inflammatory disorders of  646–649, 646t morphology of  647b, 647f pancreatic pseudocysts as  648–649 pathogenesis of  647b–648b, 648f Pancreatitis, chronic clinical features of  651 morphology of  650b, 650f the pancreas and  649–651 pathogenesis of  650b Pancreatitis, hemorrhagic  647b Pancreatitis, lymphoplasmacytic sclerosing  650b Pancytopenia  442–443 Papanicolaou smear See Cytologic (Papanicolaou) smear Papillary carcinoma of the thyroid clinical features of  733 morphology of  732b–733b, 732f summary for  735 the thyroid and  732–733 Papillary fibroelastoma  405 Papillary muscle dysfunction  383–384 Papilloma  162 Paraneoplastic syndromes  208–209, 209t Parasitic disease  585–586 Parathyroid carcinoma  736b–737b Parathyroid gland endocrine system and  735–738 hyperparathyroidism and  735–738 hypoparathyroidism and  738 Parathyroid hyperplasia  736b–737b Parenchymal hemorrhage, primary brain  817, 817f, 819 morphology of  817b Parenchymal infection arboviruses and  827 brain abscesses and  826 cytomegalovirus and  828 fungal encephalitis and  829 herpesviruses and  827–828 human immunodeficiency virus and  828 of nervous system  826–831 other meningoencephalitides as  829–831 poliovirus and  828 polyomavirus and progressive multifocal leukoencephalopathy as  828–829 rabies virus and  828 viral encephalitis and  826–829 Parenchymal injury, traumatic  820–821 morphology of  820b, 820f Parkinson disease (PD) clinical features of  839–840 morphology of  839b, 839f parkinsonism and  839–840 pathogenesis of  839b Index Paroxysmal nocturnal hemoglobinuria (PHN) hemolytic anemias and  417 pathogenesis of  417b Parvovirus B19  255–256, 256f Passive congestion circulatory disorders of liver and  633 morphology of  633b, 633f Passive smoke inhalation See Tobacco smoke, environmental Patent ductus arteriosus clinical features of  372 left-to-right shunts and  369t, 370f, 371–372 Patent foramen ovale  370–371 Pathology, introduction to  Pediatric disease congenital anomalies and  245–248, 246f fetal hydrops and  254–257 introduction to  245–268, 245t molecular diagnosis of Mendelian/complex disorders and  263–268 necrotizing enterocolitis and  252 perinatal infections and  249 prematurity/fetal growth restrictions and  249–250 respiratory distress syndrome and  250–251 sudden infant death syndrome and  252–254 tumors/tumor-like lesions and  257–262 Pemphigus (vulgaris and foliaceus) blistering disorders and  858–859, 862 clinical features of  859 morphology of  859b, 859f–860f pathogenesis of  858b–859b, 859f Penis inflammatory lesions of  657 malformations of  657 neoplasms of  657–658 Peptic ulceration, acute clinical features of  565 inflammatory disease of the stomach and  565 morphology of  565b pathogenesis of  565b Peptic ulcer disease (PUD) clinical features of  568–569 epidemiology of  568 inflammatory diseases of the stomach and  568–569 morphology of  568b, 568f pathogenesis of  565f, 568b Peptide display system  123–125 Pericardial disease heart diseases and  403–404 pericardial effusions as  404 pericarditis as  403–404 Pericardial effusion  404 Pericarditis clinical features of  403–404 morphology of  403b, 403f pericardial disease as  384, 403–404 Pericarditis, acute bacterial  403b Pericarditis, chronic  403b Pericarditis, constrictive  403b Perinatal infection  249 Peripheral nerve disorder introduction to  797–799, 798f nerve injury disorders and  798–799 patterns of injury and  797–798 summary for  800b Peripheral nerve injury disorders associated with  799t chronic inflammatory demyelinating polyneuropathy as  799 diabetic peripheral neuropathy as  799 Guillain-Barre syndrome as  798–799 summary for  800b toxic, vasculitic, inherited forms of  799–800 patterns of  797–798, 798f Peripheral nerve sheath malignant tumors of  808 neurofibromas as  807 neurofibromatosis type as  808 Schwannomas and neurofibromatosis type as  806–807 traumatic neuroma as  808 tumors of  806–808 Peripheral nerve sheath schwannoma  806–808 morphology of  807b, 807f Peripheral nerve sheath tumor, malignant  808 morphology of  808b Peripheral neuropathy summary for  800b toxic, vasculitic, inherited forms of  799, 800f Peripheral T cell lymphoma  443 Peutz-Jeghers syndrome  592–593, 594f Phagocyte oxidase  143 Phagocytosis  37–39, 39f, 112f, 114–115 Phenylketonuria (PKU)  227–228, 227f summary for  228, 228b Pheochromocytoma adrenal medulla tumors and  760–761 clinical features of  761 morphology of  760b–761b, 760f–761f Phlebothrombosis  356 See also Venous thrombosis Phyllodes tumor  707 Physical agent cell injury and  injury by electrical injury and  289 ionizing radiation and  289–293 mechanical trauma as  287 thermal injury and  288–289 toxicity of  271–272 Pickwickian syndrome  305 Pigeon breast deformity  300 Pigment  24, 25f Pilocytic astrocytoma  842–843 morphology of  843b Pituitary adenoma adrenocorticotropic hormone producing adenomas as  719–720 growth hormone producing adenomas as  719 morphology of  718b, 718f–719f other anterior pituitary neoplasms as  720 pathogenesis of  718b and pituitary gland  717–720, 717t (See also Hyperpituitarism) prolactinomas as  719 summary of  719, 720b Pituitary adenoma, nonfunctioning  720 Pituitary carcinoma  720 Pituitary gland as endocrine system  716–721, 716f–717f hyperpituitarism/pituitary adenomas and  717–720 hypopituitarism and  720–721 posterior pituitary syndromes and  721 prolactinomas and  719 PKU See Phenylketonuria (PKU) Placental-fetal transmission  318 Placental inflammation/infection  701 899 900 Index Plasma protein-derived mediator coagulation and Kinin system as  51–52 complement system as  50–51, 50f summary for  52b Plasminogen activator inhibitor (PAI)  80, 85f Platelet activation of  80, 82 adhesion and  82 aggregation of  82 discussion of  81–82 endothelial interaction with  81f, 82 normal hemostasis and  80f normal hemostasis and  79 summary for  82b Platelet-activating factor (PAF)  47–48 Platelet activation  82, 82b Platelet adherence  79 Platelet adhesion  80f–81f, 82 Platelet aggregation  81f, 82, 82b Platelet contraction  82 Pleiotropy  218–219 Pleomorphic undifferentiated sarcoma  794 Pleomorphic adenoma  163, 556–557, 557f morphology of  556b–557b Pleomorphic fibroblastic sarcoma  794, 794f Pleomorphism  165, 165f Pleural effusion  511 Pleural lesion of the lungs  511–512 malignant mesothelioma as  512 pleural effusion and pleuritis as  511 pneumothorax, hemothorax, chylothorax as  511–512 Pleuritis  511 Plexiform neurofibroma  807, 808b Plummer syndrome  728b Pneumoconiosis asbestosis as  477 coal worker’s pneumoconiosis as  475 as fibrosing disease  474–478, 474t mineral dust and  277 pathogenesis of  474b–475b silicosis as  476 summary for  478b Pneumocystis pneumonia in the immunocompromised host  501–502 morphology of  502b, 502f Pneumonia caused by other pathogens Haemophilus influenzae as  489 Klebsiella pneumoniae as  489–490 Legionella pneumophila as  490 Moraxella catarrhalis as  489 Pseudomonas aeruginosa as  490 Staphylococcus aureus as  489 community-acquired acute morphology of  488b, 489f pneumonias caused by other important pathogens and  488–490 as pulmonary infection  486–490 streptococcus pneumoniae infections as  487–488 community-acquired atypical clinical features of  490–491 influenza infections as  491 influenza virus type A/HINI infection as  491 morphology of  490b, 491f as pulmonary infections  490–491 summary for  491b in the immunocompromised host cytomegalovirus infections and  500–501 pneumocystis pneumonia and  501–502 as pulmonary infection  500–502 Pneumonia (P jiroveci) HIV infections and  151, 151t, 313 Pneumonia, chronic nontuberculous mycobacterial disease as  499 as pulmonary infection  492–499 tuberculosis and  493–498 Pneumonia, cryptogenic organizing  473–474, 474f Pneumonia, hospital-acquired  491–492 Pneumothorax  511 Podocyte injury  522f, 523, 528 Poliovirus  828 Pollution, environmental air pollution as  272–273 industrial/agricultural exposures as  276–277 metals as  273–276 Polyarteritis nodosa (PAN) autoimmune diseases and  135 clinical features of  352 morphology of  352b, 352f vasculitis and  352 Polycystic kidney disease, autosomal recessive clinical course of  544 cystic diseases and  544 morphology of  544b summary for  544 Polycystic ovarian disease  695–696 Polycythemia  425, 425t Polycythemia vera as chronic myeloproliferative disorder  447 clinical course of  447–448 morphology of  447b Polymerase chain reaction (PCR) analysis  264–266, 266f Polymerase chain reaction (PCR) analysis molecular diagnosis and  211 Polymorphism complex multigenic disorders and  234 genetic abnormalities and  216–217 linkage analysis and  245–246 P-450 enzymes and  271–272 Polymyositis  805, 806f Polyneuritis multiplex  798 Polyneuropathy  798 Polyomavirus  828–829 Polyp, endometrial  693 Polyp, hamartomatous colonic polyps and  592–593, 593t, 600 juvenile polyps as  592 Peutz-Jeghers syndrome as  592–593 Polyp, inflammatory colonic polyps as  592, 600 gastric polyps and  569, 572 morphology of  569b Polyp, juvenile  592 morphology of  592b, 594f Polyp, nomenclature for  162, 163f Polypoid cystitis (ureter)  668 Portal hypertension ascites and  609 liver disease and  608–609, 609f Portal vein obstruction/thrombosis  632–634 Portopulmonary hypertension  610 Port wine stain  357 Posterior fossa anomaly  823 Posterior pituitary syndrome  721 Index Postmortem clot  88b–89b Postnatal genetic analysis  268 Potter sequence See Oligohydramnios sequence Prader-Willi syndrome  243–245, 244f Preeclampsia/eclampsia clinical features of  704 diseases of pregnancy and  703–704 morphology of  704b summary for  704b Pregnancy, diseases of ectopic pregnancy as  701 gestational trophoblastic disease as  701–703 placental inflammations and infections as  701 preeclampsia/eclampsia as  703–704 Pregnancy, ectopic diseases of pregnancy and  701 morphology of  701b summary for  701b Prematurity, infant  249–250 Primary amyloidosis immunocyte dyscrasias as  155 lymphoplasmacytic lymphoma and  438 Primary biliary cirrhosis (PBC) cholestatic liver diseases and  627, 627t clinical course of  627 morphology of  627b–628b, 627f–628f pathogenesis of  627b Primary hypercoagulability  81f, 87 Primary immune deficiency common variable immunodeficiency as  141 genetic deficiencies of innate immunity as  142–143 hyper-IgM syndrome as  141 introduction to  139–143, 140f isolated IgA deficiency as  141 lymphocyte activation defects as  142 severe combined immunodeficiency as  142 summary for  142–143, 143b with thrombocytopenia and eczema  142 thymic hypoplasia as  141 X-linked agammaglobulinemia as  140–141 Primary sclerosing cholangitis (PSC) cholestatic liver diseases and  627t, 628–629 clinical course of  629 morphology of  628b, 629f Primary syphilis  672, 673f Primary tuberculosis  495–496, 496f Primitive neuroectodermal tumor (PNET) See Ewing sarcoma Prinzmetal angina  376 Prion  309–314 Prion disease Creutzfeldt-Jakob disease as  831 nervous system infections and  831–832, 831f variant Creutzfeldt-Jakob disease as  831 Progressive massive fibrosis (PMF)  475, 475f See also Coal worker’s pneumoconiosis (CWP) Progressive multifocal leukoencephalopathy (PML)  828–829 morphology of  829b, 829f Progressive pulmonary tuberculosis  497b Prolactinoma  719–720 Prostaglandin anti-inflammatory drugs and  46–47 arachidonic acid metabolites and  46–47 Prostate benign prostatic hyperplasia and  664–665 carcinoma of  665–668 male genital system and  663–668, 663f prostatitis and  663–664 Prostatitis clinical features of  664 prostate disease and  663–664 summary for  664b Prosthetic cardiac valve  395–396 Protein damage to  16 intracellular accumulation of  23 Protein, signal-transducing ABL and  180 introduction to  179–180 RAS protein and  179–180 Protein-coding gene alterations other than mutations epigenetic changes as  217 genetic abnormalities and  216–218 non-coding RNA alterations as  217–218 sequence and copy number variations as  216–217 mutations in  216 Protein-energy malnutrition (PEM) discussion of  294–295 kwashiorkor as  294–295 marasmus as  294 morphology of  295b secondary protein-energy malnutrition and  295 Proteoglycan  64 Protozoa  313 PSA test  211 Pseudogout  789–790 Pseudomonas aeruginosa  490 Psoriasis chronic inflammatory dermatosis and  854–855 clinical features of  854–855 morphology of  854b, 855f pathogenesis of  854b Pulmonary angiitis  485 Pulmonary anthracosis  475b Pulmonary disease as drug- and radiation-induced  478 of vascular origin diffuse alveolar hemorrhage syndromes as  485 pulmonary embolism, hemorrhage, infarction as  482–483 pulmonary hypertension as  484 Pulmonary disease, obstructive vs restrictive  462–463 Pulmonary embolism, hemorrhage, infarction clinical features of  483 diseases of vascular origin and  482–483 morphology of  482b, 483f summary for  483b Pulmonary eosinophilia  481 Pulmonary hypertension clinical features of  484 morphology of  484b, 485f pathogenesis of  484b of vascular origin  484 Pulmonary hypertension, secondary  134 Pulmonary hypertensive heart disease See Cor Pulmonale Pulmonary infection aspiration pneumonias as  492 chronic pneumonias as  492–499 community-acquired acute pneumonias as  486–490 community-acquired atypical pneumonias as  490–491 histoplasmosis, coccidioidomycosis, blastomycosis as  499–500 hospital-acquired pneumonias as  491–492 in human immunodeficiency virus infection  504 lung abscess as  492 the lungs and  486–504, 487f, 488t 901 Index 902 Pulmonary infection (Continued) opportunistic fungal infections as  502–504 pneumonia in the immunocompromised host as  500–502 Pulmonary thromboembolism  90, 90f Purulent inflammation See Inflammation, suppurative Pyelonephritis  746–747 Pyelonephritis, acute clinical course of  534f, 535 morphology of  534b–535b, 534f pathogenesis of  533b–534b, 534f summary for  537 tubulointerstitial nephritis and  533–535 Pyelonephritis, chronic clinical course of  536 morphology of  535b, 536f summary for  537 tubulointerstitial nephritis and  535–536 Pyelonephritis, chronic obstructive  535 Pyelonephritis, chronic reflux-associated  535 Pyogenic granuloma  358, 358f Pyogenic liver abscess  635 Pyogenic meningitis, acute  825 morphology of  825b, 825f Pyogenic osteomyelitis acquired bone disease and  773–774 clinical features of  774 morphology of  774b, 774f Pyrin  155–156 R Rabies virus  828 Radiation See Ionizing radiation Radiation carcinogenesis  200–201 summary for  201b Radon  273 Rapidly progressive glomerulonephritis (RPGN)  531–533 See also Crescentic glomerulonephritis anti-glomerular basement membrane antibody–mediated crescentic glomerulonephritis as  532 and glomerular diseases  531–533 immune complex–mediated crescentic glomerulonephritis as  532 pathogenesis of  532b pauci-immune crescentic glomerulonephritis as  532–533 summary for  533b RAS protein  179–180, 179f Rate of growth cancer stem cells/lineages and  166–167 neoplasms and  166–167 Raynaud phenomenon  355 RB gene  182–184 summary for  184b–185b RDS See Respiratory distress syndrome (RDS) Reactive oxygen species (ROS) accumulation of  14–16, 14f–15f cell-derived mediators and  49–50 ischemia-reperfusion injury and  17 production of  38 Reactive proliferation myositis ossificans as  793f nodular fasciitis as  793, 793f Reactive systemic amyloidosis  155 Reactive tuberculosis See Tuberculosis, secondary Recurrent sinonasal polyp  226 Red cell disorder anemia of blood loss  409 anemias of diminished erythropoiesis and  419–424 hematopoietic system and  408–425, 408t–409t hemolytic anemias and  409–419 polycythemia and  425 summary for  409b Red infarct  92b–93b, 93f, 94 Red thrombi  88b–89b Reflux esophagitis clinical features of  560–561 diseases of the esophagus and  560–561 the esophagus and  560–561 morphology of  560b, 561f pathogenesis of  560b Reflux nephropathy  535–536 Regeneration, cell and tissue control of cell proliferation and  59, 59f growth factors of  61–62 introduction to  59–65 proliferative capacities of tissue and  59–60 role of extracellular matrix in  63–65, 63f role of regeneration in tissue repair and  65 stem cells and  60 summary of  61b Rejection, acute  138 Rejection, antibody-mediated  137–138 Rejection, chronic  137f, 138 Rejection, hyperactive  137–138 Rejection, hyperacute  137–138, 137f Renal atherosclerosis  746–747 Renal cell carcinoma chromophobe renal carcinomas as  548 clear cell carcinomas as  547 clinical course of  548–549 morphology of  548b, 548f papillary renal cell carcinomas as  547–548 summary for  549b as tumors of the kidney  547–549 Renal cell carcinoma, papillary  548b Renal disease  517–518 Renal stones clinical course of  545 morphology of  545b pathogenesis of  545b, 545t urinary outflow obstruction and  545 Reperfusion  381–383, 382f Replicative potential, limitless cancer cells and  190–191, 191f summary for  191b Resorption atelectasis  460 Respiratory bronchiolitis  481 Respiratory distress syndrome (RDS) of the newborn  250–251, 250f clinical features of  251 morphology of  251b, 251f pathogenesis of  250b–251b summary  251b–252b premature infants and  249 Respiratory tract microbe transmission/dissemination through  316–319 Restrictive cardiomyopathy  401 morphology of  401b Retinoblastoma (RB) clinical features of  261 discussion of  260–261 morphology of  261b Retinoblastoma (RB) gene  182–184 pathogenesis of  183f Retinopathy, diabetic  744, 747, 747f Retroperitoneal fibrosis (ureter)  668 Rhabdomyomas  404b Index Rhabdomyosarcoma  794–795 morphology of  795b, 795f Rheumatic fever, acute  391b Rheumatic heart disease  110, 391b Rheumatic valvular disease clinical features of  391–392 morphology of  391b, 392f pathogenesis of  391b valvular heart disease as  391–392 Rheumatoid arthritis (RA) autoimmune diseases  131 clinical features of  785–786 of the joints  784–786 morphology of  785b, 785f–786f pathogenesis of  784b, 784f summary for  790 Rheumatoid vasculitis  355 Rickets acquired bone disease and  771 morphology of  300b–301b vitamin D and  298–300, 300f Rickettsia  311–313 Riedel thyroiditis  726 RNA virus, oncogenic  201, 201f summary for  202b Rolling  35–37, 36t ROS See Reactive oxygen species (ROS) Rotavirus  585–586 Roundworms (nematode)  314, 314f S Sacrococcygeal teratoma  258, 258f Saddle embolus  90, 90f Salivary gland, disease of neoplasms as  555–557 sialadenitis as  555 summary for  557b xerostomia as  555 Salmonellosis infectious enterocolitis and  583–584 pathogenesis of  584b Sanger sequencing  265, 266f Sarcoidosis clinical features of  480 epidemiology of  478–479 etiology and pathogenesis of  479b as granulomatous disease  478–480 morphology of  479b–480b, 479f summary for  480b Sarcoma  162 Sarcoma botryoides  685 Scar formation angiogenesis and  66–67 connective tissue remodeling and  68 fibroblasts and connective tissue in  68 growth factors involved in  42f, 68 introduction to  65–68 remodeling of connective tissue and  68 steps in  65–66, 66f summary for  69b Scarring chronic inflammation and  309–314 morphology of  325b, 325f Scleroderma See Systemic sclerosis (SS) Scleroderma, limited  132 Sclerosing adenosis  706 morphology of  706b, 706f Scrotum  658–663 Scurvy  301 Seborrheic keratosis as epithelial lesions of the skin  862–863 morphology of  862b, 862f Secondary immune deficiency  143 Secondary syphilis  672–673 Secondary tuberculosis clinical features of  498 morphology of  497b, 497f–498f as type of tuberculosis  496 Seminoma  163 Sensorimotor polyneuropathy, distal symmetric  799 Septic shock  94, 95f Sequence  216–217 Sequencing, whole genome  212–213, 212f–213f Serous carcinoma  692b, 693f Serous cystadenoma  651, 651f Serous tumor, ovarian epithelial  697 morphology of  697b, 697f Severe combined immunodeficiency (SCID)  142–143 Sexually transmitted disease (STD) chancroid as  677 genital herpes simplex as  678 gonorrhea and  674–675 granuloma inguinale as  677 human papillomavirus infection as  678 lymphogranuloma venereum as  676 male genital system and  671–678, 671t microbe dissemination and  318 nongonococcal urethritis and cervicitis as  676 trichomoniasis as  677–678 Sézary syndrome  443 Sheehan postpartum pituitary necrosis  452b Shigellosis clinical features of  584b infectious enterocolitis and  583 morphology of  583b pathogenesis of  583b Shock clinical course for  97 introduction to  94–97, 94t morphology of  97b pathogenesis of  94–96 stages of  96–97 summary for  97b Shock lung  97b Shunt, left-to-right atrial septal defect/patent foramen ovale and  370–371 congenital heart disease and  370–372, 370f patent ductus arteriosus and  371–372 ventricular septal defects and  371 Shunt, portosystemic hepatorenal syndrome and  610 liver disease and  609–610 portopulmonary hypertension/hepatopulmonary syndrome and  610 splenomegaly and  609 Shunt, right-to-left congenital heart disease and  372–373, 372f tetralogy of Fallot and  372–373 transposition of the great arteries and  373 Sialadenitis  555, 556f, 557 Sicca syndrome  131 Sickle cell anemia clinical course of  413 hemolytic anemias and  411–413 incidence of  411–413 morphology of  411f, 412b–413b 903 904 Index Sickle cell anemia (Continued) pathogenesis of  411b–412b, 412f summary for  419 SIDS See Sudden infant death syndrome (SIDS) Sigmoid diverticulitis clinical features of  586–587 inflammatory intestinal disease and  586–587 morphology of  586b, 586f, 591f pathogenesis of  586b summary for  587b Silicosis clinical features of  476 morphology of  476b, 476f as pneumoconiosis  476 summary for  478 Single-gene disorder with atypical patterns of inheritance  241–244 alterations of imprinted region disease as  243–244 mutations in mitochondrial genes disease as  243 triplet repeat mutations as  241 Single-gene disorder, transmission patterns of autosomal dominant inheritance as  219–220 autosomal recessive inheritance as  220 summary for  220b X-linked disorders as  220 Single-nucleotide polymorphism (SNP)  222–223 array-based genomic hybridization and  264 linkage analysis and  266 sequence and copy number variations and  216–217 Sinusoidal obstruction syndrome  634, 634f Sinus venosus ASD  371b Sjögren syndrome discussion of  131–132 morphology of  132b, 132f pathogenesis of  127t, 131b summary for  132b Skeletal muscle acquired disorders of  805–806 inflammatory myopathies as  805 toxic myopathies as  805–806 inherited disorders of  802–805 channelopathies, metabolic and mitochondrial myopathies as  805 dystrophinopathies as  802–804 X-linked and autosomal muscular dystrophies as  804–805 patterns of injury for  801–802, 803f summary for  806b Skeletal muscle tumor, rhabdomyosarcoma as  794–795 Skin benign and premalignant tumors of  862–869 blistering disorders of  857–861 chronic inflammatory dermatoses and  854–856 infectious dermatoses and  856–857 introduction and terminology for  851 microbe transmission/dissemination and  316, 318–319 SLE morphology and  130, 130f systemic sclerosis morphology and  133, 134f Skin wound healing by first intention and  70–71, 70f healing by second intention and  70f–71f, 71–72 summary for  72b wound strength and  72 Small airway disease See Chronic bronchiolitis Small cell carcinoma (SCLC)  506b–509b, 509f Small-for-gestational-age (SGA) infant  249–250 Small lymphocytic lymphoma (SLL)  433–434 summary for  443 Smog  272–273 Smokeless tobacco  277, 279 Smoking-related interstitial disease  481, 482f and chronic interstitial lung disease  481 Sodium retention  77–78 Soft tissue fibrohistiocytic tumors and  794 fibrous tumors and tumor-like lesions of  792 introduction to  791–796, 792t skeletal muscle tumors and  794–795 smooth muscle tumors and  795 synovial sarcoma and  795 tumors of adipose tissue and  792 Spermatocytic seminoma  660b–662b Spider telangiectasias  357–358 Spinal cord abnormality  823 Spinocerebellar ataxia (SCA)  840–841 Spirochetal infection neuroborreliosis as  826 neurosyphilis as  826 Spleen  456–457 amyloidosis and  157 SLE morphology and  130 splenomegaly as  456 Splenomegaly CML and  447 hairy cell leukemia and  442–443 portosystemic shunt and  609 spleen disorders and  456 Spondyloarthropathy, seronegative  786 Spontaneous maturation  258–259 Spontaneous regression  258–259 Squamous cell carcinoma clinical features of  863–864 of the esophagus  563–564 clinical features of  563–564 morphology of  563b, 563f pathogenesis of  563b lung tumors and  506b–509b malignant epidermal tumors and  863–864 morphology of  863b, 864f nomenclature for  162–163, 165f of the oral cavity  554 morphology of  554b, 555f pathogenesis of  554b pathogenesis of  863b of the vagina  684 Staging, cancer tumor and  208–210 Staphylococcus aureus  489 Stasis thrombi See Red thrombi Steatohepatitis, nonalcoholic  305 Steatosis See Fatty change Steatosis, drug/toxin-mediated injury with  625 morphology of  626b Steatosis, hepatocellular  621b–622b, 621f Stem cell  60, 61b, 61f cancer of  166–167 Stem cell, adult  60 Stem cell, cardiac  385 Stem cell, embryonic (ES cell)  60 Stenting, endovascular  362, 363f Stomach carcinoid tumor as  571–572 gastric adenocarcinoma as  570–571 gastric polyps as  569 gastrointestinal stromal tumor as  572 inflammatory diseases of  564–569 acute gastritis as  564 acute peptic ulceration as  565 Index chronic gastritis as  565 peptic ulcer disease as  568–569 lymphoma as  571 neoplastic disease of  569–572 carcinoid tumor as  571–572 gastric adenocarcinoma as  570–571 gastric polyps as  569 gastrointestinal stromal tumor as  572 lymphoma as  571 summary for  572b–573b Streptococcus pneumoniae infection  487–488 Stress cellular adaptations to  3–5 cellular response to  1–3, 2f Structural abnormality, cytogenetic disorders and  235–236, 235f–236f Sturge-Weber syndrome  257–258 See also Port wine stain Subdural hematoma  821–822 morphology of  821f, 822b Subdural infection of nervous system  824–825 Sudden cardiac death (SCD)  386, 386f Sudden infant death syndrome (SIDS) discussion of  252–254, 253t morphology of  253b pathogenesis of  253b summary for  254b Sulfur dioxide  273 Superior vena cava syndrome  356 Surface epithelial tumor (ovarian)  696–697 Syndrome of inappropriate ADH (SIADH)  721 Synovial cyst  790 Synovial sarcoma morphology of  795b–796b, 795f soft tissue disease and  795–796 Syphilis congenital syphilis and  673–674 male genital system and  671–674 morphology of  672b primary syphilis and  672, 673f secondary syphilis and  672–673 serologic tests for  674 summary for  674b tertiary syphilis and  673 Systemic disease diet and  306 Systemic immune complex disease  116–117, 116f Systemic inflammatory response syndrome (SIRS)  94–95 Systemic lupus erythematosus (SLE) autoantibodies in  127 as autoimmune disease  125–131, 125t clinical manifestations of  127t, 131 mechanisms of tissue injury in  127–131 morphology of  125t, 128b–130b, 129f pathogenesis of  125b–127b, 126f summary for  131b Systemic miliary tuberculosis  497b Systemic sclerosis (SS) as autoimmune disease  132–134 clinical course for  134 morphology of  133b–134b pathogenesis of  133b, 133f summary for  134b–135b T Tapeworm (cestode)  314 Tay-Sachs disease  229–230, 230f T cell HIV and  146 systemic sclerosis and  133 T cell leukemia, adult  443 T cell lymphoma, adult  443 T cell-mediated hypersensitivity (Type IV) CD4+ T cell inflammatory reactions and  118–119 delayed-type hypersensitivity and  119 introduction to  111, 117–120, 118t, 119f summary for  120b T cell-mediated cytotoxicity and  119–120 T cell mediated rejection  137 T cell receptor (TCR)  101, 101f Tenosynovial giant cell tumor (TGCT) clinical features of  791 joint tumors and  790 morphology of  790b, 791f Teratoma, benign cystic  163, 698–700, 700f Teratoma, immature malignant  700 Teratoma, specialized  700 Tertiary syphilis  673 Testicular atrophy  658–659 Testicular neoplasm  659–663, 660t clinical features of  662–663 morphology of  660b–662b, 660f–662f summary for  663b Testicular torsion  659 Testis cryptorchidism/testicular atrophy and  658–659 inflammatory lesions of  659 male genital system and  658–663 neoplasms of  659–663 vascular disturbances and  659 Tetany, hypocalcemic  298 Tetralogy of Fallot clinical features of  372–373 morphology of  372b right-to-left shunts and  369t, 372–373, 372f Thalassemia clinical course of  416 hemolytic anemias and  413–416 morphology of  415b–416b pathogenesis of  413b–415b, 414f–415f, 414t summary for  419 Thanatophoric dwarfism  767 Thermal burn morphology of  288b–289b thermal injury and  288 Thermal injury hyperthermia as  289 hypothermia as  289 thermal burns as  288 Thiamine deficiency  835 Thoracic aortic aneurysm  346 Thrombocytopenia, heparin-induced  453 Thrombin coagulation cascade and  81f, 83, 85f platelet aggregation and  82 Thromboangiitis obliterans (Buerger disease)  354–355 clinical features of  354–355 morphology of  354b, 354f Thrombocytopenia  78, 87, 424 disseminated intravascular coagulation and  452–454, 453t heparin-induced thrombocytopenia and  453 immune thrombocytopenic purpura and  452–453 thrombotic microangiopathies as  453–454 Thrombocytopenic syndrome, heparin-induced  87 905 906 Index Thromboembolism embolism and  75, 90 HRT and  283 oral contraceptives and  284 Thromboembolism, systemic air embolism as  91–92 amniotic fluid embolism as  91 embolism and  91–92 fat embolism as  91 Thrombophlebitis  356 Thromboplastin See Endothelial injury Thrombosis abnormal blood flow and  86 clotting and  75 endothelial injury and  86 fate of thrombus and  89 hypercoagulability and  87–88 introduction to  86–89, 86f morphology of  88b–89b, 88f summary for  90b Thrombotic microangiopathy pathogenesis of  453b–454b summary for  541 as blood vessel disease of the kidney  540–541 clinical course of  541 morphology of  541b pathogenesis of  540b–541b summary of  541 thrombocytopenia and  453–454 Thrombotic thrombocytopenic purpura (TTP)  541 summary for  456 thrombotic microangiopathies and  453–454 Thromboxane  46 Thrombus clinical correlations for  89 venous thrombosis and  89 fate of  89, 89f Thrush See Oral candidiasis Thymic carcinoma  457b Thymic hyperplasia  457 Thymic hypoplasia  141 Thymoma clinical features of  457 morphology of  457b thymus disorders and  457 Thymoma type I, malignant  457b Thymus disorder introduction to  456–457 thymic hyperplasia as  457 thymoma as  457 Thyroid diffuse/multinodular goiter and  728 and endocrine system  721–735, 722f Graves disease as  726–727 hyperthyroidism and  722–723 hypothyroidism and  723–724 neoplasms of  728–735 adenomas as  729–730 carcinomas of  730–735 introduction to  728–735 summary of  735b thyroiditis as  724–726 Thyroiditis chronic lymphocytic and clinical features of  725 hypothyroidism and  724–725 morphology of  724b–725b, 725f pathogenesis of  724b, 725f chronic lymphocytic (Hashimoto) and summary for  726 chronic lymphocytic thyroiditis and  724–725 other forms of thyroiditis and  726 subacute granulomatous thyroiditis and  725–726 subacute granulomatous thyroiditis (de Quervain) and clinical features of  726 morphology of  726b summary for  726 the thyroid and  725–726 subacute lymphocytic thyroiditis and  726 summary of  726b and the thyroid  724–726 Thyrotoxic myopathy  806 Thyrotroph adenoma  720 Tinea  313 Tissue injury morphology of  8–11 SLE mechanisms of  127–131 summary of  11b Tissue injury, leukocyte-induced  39–40, 41t Tissue necrosis See also Necrosis inflammatory response to infection by  324 morphology of  324b morphology of  9b patterns of  9–11 summary of  11 Tissue repair clinical examples of  70–72 fibrosis in parenchymal organs and  72 healing skin wounds and  70–72 influencing factors of  69–70, 69f overview of  29–30, 58–59, 58f role of extracellular matrix in  63–65 summary for  64b role of regeneration in  65, 65f T lymphocyte cell-mediated immunity and  105–108 effector functions of  107–108, 107f immune system and  101–102, 101f summary for  104 Tobacco smoke carcinogens in  279, 279t combined with alcohol  279, 279f components of  278–279, 279t discussion of  277–279, 278t effects of  277–278, 278f–279f, 278t, 280 indirect-acting chemicals and SLE and  126 summary for  280b Tobacco smoke, environmental  279 Toll-like receptor (TLR)  32, 32f, 52 Total-body irradiation  293, 293t Toxic agents, agricultural exposure to  276–277 Toxic disorder, nervous system and  835–836 Toxic metabolite  271, 271f–272f Toxic myopathy  805–806 TP53 gene evasion of cell death and  190 as guardian of genome  185–187, 186f summary for  187b tumor suppressor gene as  173 Transforming growth factor-β pathway (TGF-β pathway) discussion of  187 summary of  188b–189b Transmigration  36 Transmural infarct  379 Index Transplant effector mechanisms of graft rejection and  137–138 hematopoietic stem cell transplant and  139 immune recognition of allografts and  135–136 summary for  138b improving graft survival and  138–139 morphology of  137b–138b, 137f rejection of  135–139 Transposition of the great arteries clinical features of  373 right-to-left shunts and  372f, 373 Trauma central nervous system and  820–822 summary of  822b parenchymal injuries and  820–821 vascular injury and  820–821 Traumatic hemolysis  418 Traumatic neuroma  798f, 808 Trichomoniasis  677–678 Trisomy 21 (Down syndrome)  237, 238f, 239 Trophoblastic tumor, placental site  703 summary for  703 Trophozoite  313 Tuberculosis as chronic pneumonia  493–498 etiology of  493 morphology of  495b, 495f–496f pathogenesis of  493b–495b, 494f primary tuberculosis and  495–496 secondary tuberculosis and  496 summary for  499b Tuberculous meningitis  826 morphology of  826b Tuberculous osteomyelitis  774 Tuberous sclerosis (TSC)  847 morphology of  847b Tubules and interstitium, disease affecting acute tubular injury and  537–538 the kidney and  533–538 tubulointerstitial nephritis as  533–537 Tubulointerstitial nephritis (TIN) acute pyelonephritis as  533–535 chronic pyelonephritis and reflux nephropathy as  535–536 diseases affecting tubules/interstitium and  533–537 drug-induced interstitial nephritis as  536–537 summary for  537b Tumor of adipose tissue lipoma and  792 liposarcoma and  792 of the adrenal medulla neuroblastoma and  761 pheochromocytoma as  760–761 of the appendix  601 of the bone bone-forming tumors and  775–777 cartilage-forming tumors and  777–779 diseases of the bone and  774–781, 775t fibrous/fibroosseous tumors and  779–780 miscellaneous bone tumors and  780–781 summary for  781b–782b of the breast  707–713 carcinoma as  708–713 fibroadenoma as  707 intraductal papilloma as  708 phyllodes tumor as  707 of the central nervous system embryonal neoplasms as  844–845 familial tumor syndromes as  847 introduction to  842–847 meningiomas as  846 metastatic tumors as  846–847 neuronal tumors as  844 other parenchymal tumors as  845 summary for  847b–848b effects on host  207–208 of infancy/childhood benign tumors and  257–258, 257f clinical course and prognosis for  259–260 of the joint ganglion and synovial cysts as  790 joint disease and  790–791 tenosynovial giant cell tumor as  790–791 of the kidney  547–549 oncocytoma as  547 renal cell carcinoma as  547–549 Wilms tumor as  549 of the liver benign tumors as  635–639 hepatocellular carcinomas as  637–639 liver diseases and  635–639 precursor lesion of hepatocellular carcinoma as  636–637 summary for  639b of the lung carcinoid tumors as  510–511 carcinomas and  505–510 introduction to  505–511 neoplasia and  162 of the ovary Brenner tumor and  698 clinical correlations of  700 endometrioid tumors and  698 introduction of  696–698, 696f mucinous tumors and  697–698 serous tumors and  697 summary for  700b surface epithelial tumors and  696–697 of the skin benign and premalignant epithelial lesions as  862–863 malignant epidermal tumors as  863–864 melanocytic proliferations as  865–869 of the ureter  668 of the vulva  683–684 carcinoma and  683 condylomas and  683 extramammary Paget disease and  683–684 Tumor, benign focal nodular hyperplasia as  635–636 hepatic adenoma as  636 of infancy and childhood  259–260 of the liver  635–636 Tumor, dysembryoplastic neuroepithelial  844 Tumor, endometrioid  698 Tumor, fibrohistiocytic benign fibrous histiocytoma as  794 pleomorphic fibroblastic sarcoma/pleomorphic undifferentiated sarcoma  794 and soft tissue  794 Tumor, fibroosseous  779–780 Tumor, fibrous of the bone fibrous cortical defect and nonossifying fibroma as  779 fibrous dysplasia as  779–780 907 908 Index Tumor, fibrous (Continued) fibromatoses and  793 fibrosarcoma as  793–794 reactive proliferations and  793 of the soft tissue  792–794 Tumor, germ cell  845 Tumor, Krukenberg  698b Tumor, malignant in infancy and childhood  258–262, 258t neuroblastoma as  258–260 retinoblastoma as  260–261 Wilms tumor as  261–262 Tumor, malignant epidermal basal cell carcinoma as  864 squamous cell carcinoma as  863–864 summary for  864b Tumor, neuronal  844 Tumor, odontogenic  558 Tumor, parenchymal germ cell tumors as  845 primary central nervous system lymphoma as  845 Tumor, smooth muscle leiomyoma as  795 leiomyosarcoma as  795 Tumor, vascular benign and tumor-like conditions of  357–359 intermediate-grade of  360–361 introduction to  357–362, 357t malignant tumors as  361–362 summary for  362b Tumor antigen differentiation antigens and  206 glycolipids/glycoproteins and  206 introduction to  204–206, 205f mutated oncogenes/tumor suppressor genes and  204–205 oncofetal antigens and  206 oncogenic viruses and  206 other mutated genes and  205 overexpressed cellular proteins and  205 Tumor cell, homing of  194–195 Tumor immunity antigens and  204–206 introduction to  204–207 surveillance and evasion by  207 Tumor marker  211 Tumor necrosis factor (TNF)  48, 48f Tumor suppressor gene carcinogenesis and  173, 177, 184 inherited mutations and  171–172 Turner syndrome  240–241, 240f nonimmune hydrops and  255–256 22q11.2 deletion syndrome  237–239 Type diabetes (T1D) clinical features of  748, 750t diabetes mellitus and  739 pathogenesis of  741, 741f summary for  750 Type diabetes (T2D) clinical features of  748, 750t diabetes mellitus and  739 pathogenesis of  741, 742f summary for  750 Type hypersensitivity See Hypersensitivity, immediate Type II hypersensitivity See Antibody-mediated disease Type III hypersensitivity See Immune complex disease Type I interferon, SLE and  126 Typhoid fever  584 Tyrosine kinases, non-receptor  178–179 U Ultraviolet (UV) radiation  126 Upper respiratory tract acute infection  512–513 Upper respiratory tract lesion acute infections and  512–513 laryngeal tumors and  513–514 nasopharyngeal carcinoma and  513 Ureaplasma  313 Ureter  668–671 Ureteropelvic junction (UPJ) obstruction  668 Urinary bladder neoplasms of  669–671 non-neoplastic conditions of  668–669 Urinary outflow obstruction hydronephrosis and  545–547 renal stones and  545 Urinary tract infection  518 Urogenital tract  317, 319 Urolithiasis  545 Urticaria acute inflammatory dermatoses and  852 clinical features of  852 morphology of  852b pathogenesis of  852b Uterus, body of abnormal uterine bleeding and  690–691, 690t adenomyosis and  689 endometriosis and  689–690 endometritis and  689 proliferative lesions of endometrium/myometrium and  691–694 summary for  691b V Vagina female genital system and  684–685 malignant neoplasms of  684–685 clear cell adenocarcinoma as  685 sarcoma botryoides as  685 squamous cell carcinoma as  684 vaginitis and  684 Vaginitis  684 Variant Creutzfeldt-Jakob disease (vCJD)  831, 832f Varicose vein of the extremities  356 clinical features of  356 of other sites  356 Vascular change acute inflammation and  31, 31f, 33–34 changes in vascular caliber and flow and  31f, 33–34 increased vascular permeability and  33–34, 33f lymphatic vessel responses and  34 summary of  34b Vascular dissemination invasion-metastasis cascade and  194–195 Vascular ectasias  357–358 Vascular injury, traumatic central nervous system and  821–822, 821f epidural hematoma as  821 subdural hematoma as  821–822 Vascular intervention, pathology of endovascular stenting and  362 vascular replacement and  363 Index Vascular malformation  818 morphology of  818b–819b, 819f Vascular organization  328–329, 328f Vascular replacement  363 Vascular smooth muscle cell  330 Vascular tumor, benign bacillary angiomatosis as  359 glomus tumors as  359 hemangiomas as  358–359 lymphangiomas as  359 vascular ectasias as  357–358 Vascular tumor, intermediate-grade hemangioendotheliomas as  361 Kaposi sarcoma as  360–361 Vascular tumor, malignant angiosarcomas as  361–362 hemangiopericytomas as  362 Vascular wall, response to injury by intimal thickening and  334–335, 335f Vasculitis  819 discussion of  348–355, 349f infectious type of  355 noninfectious type of  348–355 summary for  355b Vasoactive amines  112 Vein, disease of superior and inferior vena cava syndromes as  356 thrombophlebitis and phlebothrombosis as  356 varicose veins of the extremities as  356 Velocardiofacial syndrome  237–239 Venoocclusive disease See Sinusoidal obstruction syndrome Venous thrombosis (phlebothrombosis)  87t, 89 paroxysmal nocturnal hemoglobinuria and  417b Ventricular aneurysm  383f, 384 Ventricular septal defect clinical features of  371 left-to-right shunts and  369t, 371, 371f morphology of  371b Verrucae (warts) infectious dermatoses and  857 morphology of  857b, 858f pathogenesis of  857b Verrucous endocarditis  88b–89b Verrucous endocarditis, nonbacterial  130 Viral encephalitis  826–829, 827f Viral hepatitis, acute  619 Viral injury, mechanism of  319–320, 319f Viral meningitis See Aseptic meningitis Virchow’s triad  86, 86f Virus autoimmunity and  124 infectious agents as  309–310, 310t, 311f Virus, oncogenic  206 Vitamin A deficiency states of  297–298 discussion of  296–298, 297f–298f function of  296–298 toxicity of  298 Vitamin B12 deficiency  835 Vitamin B12 deficiency anemia clinical features of  423 as megaloblastic anemia  423 pathogenesis of  423b Vitamin C (ascorbic acid) deficiency of  301 discussion of  301–302 function of  301–302 toxicity of  301–302 Vitamin D deficiency states of  299–301, 301f discussion of  298–301 functions of  299, 299f metabolism of  298–299, 299f toxicity of  301 Vitamin deficiency nutritional disease and  296–302, 302t–303t Vitamin A and  296–298 Vitamin C and  301–302 Vitamin D and  298–301 Von Gierke disease  232–233, 233t von Hippel-Lindau disease  847 morphology of  847b Von Willebrand disease  455 summary for  456 von Willebrand factor (vWF)  80, 81f Vulva non-neoplastic epithelial disorders of  682 tumors of  683–684 summary for  684b vulvitis and  681–682 Vulvitis  681–682 W WAGR syndrome  261–262 Waldenström macroglobulinemia  439–440 Warts See Verrucae Waterhouse-Friderichsen syndrome disseminated intravascular coagulation and  452b metabolic abnormalities and  96 Water retention  77–78 Wegner granulomatosis (WG)  353–354 clinical features of  354 diffuse alveolar hemorrhage syndromes and  485 morphology of  353b–354b, 353f Wernicke-Korsakoff syndrome  281, 302t, 835 morphology of  835b White cell disorder hematopoietic system and  425–449 neoplastic proliferations of histiocytic neoplasms and  449 neoplastic proliferations of  428–449 lymphoid neoplasms and  429–443 myeloid neoplasms as  444–448 as white cell disorders  428–449 non-neoplastic disorders of  425–428 leukopenia as  425–426 reactive leukocytosis as  426–427 reactive lymphadenitis as  427–428 White infarcts  92b–93b, 93f, 94 Wilms tumor discussion of  261–262 morphology of  262b, 262f–263f summary for  262b–263b tumors of the kidney and  549 Wilson disease clinical features of  631 as inherited metabolic disease  630–632 morphology of  631b pathogenesis of  631b Wood smoke  273 Wrist, carpal ligaments of  157–158 909 910 Index X Y Xenobiotics  271, 271f–272f summary for  273 Xeroderma pigmentosum  197 Xerophthalmia (dry eye)  297–298 Xerostomia  131, 132b, 555 X-linked agammaglobulinemia (XLA)  140, 143 X-linked disorder  220 Yellow fever  620 Yolk sac tumor  660b–662b, 661f Z Zollinger-Ellison syndrome  568b ... Tumors Benign Malignant Pleomorphic adenoma (50%) Warthin tumor (5%) Oncocytoma (2% ) Cystadenoma (2% ) Basal cell adenoma (2% ) Mucoepidermoid carcinoma (15%) Acinic cell carcinoma (6%) Adenocarcinoma... otherwise specified Data from Ellis GL, Auclair PL, Gnepp DR: Surgical Pathology of the Salivary Glands, Vol 25 : Major Problems in Pathology, Philadelphia, WB Saunders, 1991 benign from malignant lesions... (tTG) Deamidated gliadin APC HLA (DQ2 or DQ8) T MIC-A IL-15 IFNg T T cell receptor B NKG2D B cell receptor Anti-gliadin Anti-endomysium Anti-tTG Figure 14 21   Left panel, The morphologic alterations

Ngày đăng: 21/01/2020, 17:04

TỪ KHÓA LIÊN QUAN